SARS-CoV-2 neutralizing antibody development strategies

Turkish journal of biology

article

BERTAN KORAY BALCIOĞLU¹  MELİS DENİZCİ ÖNCܹ  HASAN ÜMİT ÖZTÜRK¹  FATIMA YÜCEL¹  FİLİZ KAYA¹  MÜGE SERHATLI¹  HİVDA ÜLBEĞİ POLAT¹  ŞABAN TEKİN¹  AYLİN ÖZDEMİR BAHADIR¹ 

[1] Genetic Engineering and Biotechnology Institute, Marmara Research Center;Department of Basic Medical Sciences, Faculty of Medicine, University of Health Sciences

关键词: SARS-CoV-2;    COVID-19;    neutralizing antibodies;    human monoclonal antibody;    display technologies;    human scFv;    neutralizing assays;    animal models;   

DOI  :  10.3906/biy-2005-91

学科分类：生物科学（综合）

来源: Scientific and Technical Research Council of Turkey - TUBITAK

【 摘 要 】

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

【 授权许可】

Unknown